Bevacizumab Against Recurrent Retinal Detachment

NCT02192970 ↗

Phase 2 Completed 101 enrolled University of Wisconsin, Madison

Non-randomizedSingle-groupOpen-labelPrevention

Summary

The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.

Timeline

Start: 2015-01-21
Primary completion: 2019-11-11
Completion: 2019-11-11

Publications

Background Pennock S, Kim D, Mukai S, Kuhnle M, Chun DW, Matsubara J, Cui J, Ma P, Maberley D, Samad A, Van Geest RJ, Oberstein SL, Schlingemann RO, Kazlauskas A. Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease. Am J Pathol. 2013 May;182(5):1659-70. doi: 10.1016/j.ajpath.2013.01.052. Epub 2013 Apr 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	—	Intravitreal

Bevacizumab Against Recurrent Retinal Detachment

Summary

Timeline

Publications

Drugs

Indications